Carbajal-Ugarte JA, Cárdenas-Blanco A, Pastrana-Huanaco E, López-Berrios D

Language: Spanish
References: 14
Page: 83-87
PDF size: 120.51 Kb.

ABSTRACT

Objective: to determine the efficacy and adverse effects of subdermic implants, oral and injectable contraceptives.
Methods: the study was conducted by using a cross-sectional design. The efficacy was measured by using the Pearl Index (PI) and the adverse effects were registered in each type of contraceptive: oral, injectable and subdermic implant.
Results: 264 users were included, the median age was 23.6 years and the mean weight was 54.48 kg. 23.1% were oral contraceptives users; 15.7% were using injectable contraceptives and 56.8% were using subdermic implants. The average time of contraceptive use was 13.4 months. Regarding efficacy, the subdermic implants had a PI of 0; oral contraceptives showed a PI of 0.13, and the PI of injectable contraceptives was 0. Regarding adverse effects, these were reported by 84.7% of subdermic implants users, 18.0% of oral users and 23.3% of injectable users.
Conclusion: the efficacy of these three types of contraceptives is appropriate. The adverse effects are more frequent among implants users. The oral and injectable hormonal are effective and safe as contraceptive method and show less adverse effects than subdermic implants.

REFERENCES

1. Mateo de Acosta O, Licea M. Contraceptivos hormonales inyectables. Rev Cubana Obstet Ginecol 1984;10:39-51.

2. Toppozada M. The clinical use of monthly injectable contraceptive preparations. Obstet Gynecol Surv 1977;32:335-347.

3. Gómez M, Romero J, Hernández MI, Mojena ML. Eficacia de dos contraceptivos inyectables (cycloprovera y HRP-102 administrados mensualmente por vía intramuscular). Rev Cubana Obstet Ginecol 1989;15:42-53.

4. Gray RH. Patterns of bleeding associated with the use of steroidal contraceptives En: Diczalusy S, Fraser IS, Webb FTS. Endometrial bleeding and steroidal contraception. Bath, United Kingdom: Pitman; 1980. p. 19-44.

5. Grupo de trabajo del Programa DAPHNE. Análisis del cumplimiento en anticoncepción hormonal oral (AHO). Madrid, España: Grupo Aula Médica; 1996.

6. Gardner J, Miller L. Promoting the safety and use of hormonal contraceptives. J Womens Health (Larchmt) 2005;14(1):53-60.

7. Moreno L, Goldman N. Contraceptive failure rates in developing countries: evidence from demographic and health surveys. Int Fam Plann Perspect 1991;17(2):44-49.

8. Bitzer J, Tschudin S, Alder J. Acceptability an side-effects of implanon in Switzerland: a retrospective study by the Implanon Swiss Study Group. Eur J Contracept Reprod Health Care 2004;9(4):278-284.

9. Affandi B, Korver T, Geurts TB, Coelingh-Bennink HJ. A pilot efficacy study with a single-rod contraceptive implant (Implanon) in 200 Indonesian women treated for ≤ 4 years. Contraception 1999;59(3): 167-174.

10. Booranabunyat S, Taneepanichskul S. Implanon use in Thai women above the age of 35 years. Contraception 2004;69(6):489-491.

11. Manual de Actualización en metodología anticonceptiva. México: IMSS; 2002.

12. Vloten WA, Sigurdsson V. Selecting an oral contraceptive agent for the treatment of acne in women. Am J Clin Dermatol 2004:5(6):435-441.

13. Allais G, De Lorenzo C, Mana O, Benedetto C. Oral contraceptives in women with migraine: balancing risks and benefits. Neurol Sci 2004;25(Suppl 3):S211-S214.

14. Morroni C, Grams M, Tiezzi L, Westhoff C. Immediate monthly combination contraception to facilitate initiation of the depot medroxyprogesterone acetate contraceptive injection. Contraception 2004;70(1):19-23.